San Diego-based mostly Viking Therapeutics marked alone as a significant competitor during the weight loss drug market place in February just after revealing promising knowledge from the mid-stage demo of experimental drug VK2735, which proposed it rivaled—and outperformed—Novo and Lilly drugs when supplied as being a weekly injection and in Ma